Methods of determining responsiveness to anti-TNFα therapy in inflammatory bowel disease
AssigneeCedars-Sinai Medical Center
InventorsJerome I. Rotter, Marla Dubinsky, Stephan R. Targan, Kent D. Taylor
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of prognosing responsiveness to anti-TNFα therapy by determining the presence or absence of risk factors in the individual. In one embodiment, the risk factors are genetic markers, serological markers and/or clinical phenotypes associated with non-responsiveness to treatment with anti-TNFα therapy in an individual diagnosed with IBD.
Claims20
A method for treating inflammatory bowel disease in a subject, the method comprising:
- predicting whether a subject with an inflammatory bowel disease will suffer from non-response to an anti-Tumor necrosis factor (TNF) therapy for treatment of the inflammatory bowel disease, comprising:
- (i) obtaining or having obtained a biological sample from the subject;
- and
- (ii) performing or having performed a genotyping assay on the biological sample to determine if the subject carries one or more genetic risk factors for non-response to anti-TNF therapy comprising a risk allele that is a C allele at rs666595;
- and
- if the subject does not carry any of the genetic risk factors, then administering to the subject an anti-TNF therapy,
- if the subject does carry at least one of the genetic risk factors, then administering to the subject an active agent for treatment of the inflammatory bowel disease that does not directly target TNF.
A method for treating an inflammatory bowel disease in a subject, the method comprising:
- (a) hybridizing a risk allele-specific oligonucleotides to a nucleic acid sequence of one or more genetic risk factors, that are predictive of non-response to an anti-TNF therapy for treatment of the inflammatory bowel disease, in a biological sample obtained from a subject with an inflammatory bowel disease, wherein the one or more genetic risk factors comprise a risk allele that is a C allele at rs666595;
- (b) detecting binding of the risk allele-specific oligonucleotides to the one or more genetic risk factors;
- and
- (c) administering to the subject an active agent for treating the inflammatory bowel disease that does not directly target TNF.
A method for treating inflammatory bowel disease in a subject, the method comprising:
- (a) screening a genome of a subject with an inflammatory bowel disease for one or more genetic risk factors associated with a risk of non-response to an anti-TNF therapy for treatment of the inflammatory bowel disease utilizing a nucleic acid amplification assay, wherein the one or more genetic risk factors comprises a risk allele that is a C allele at rs666595;
- (b) detecting the presence of the one or more genetic risk factors;
- and
- (c) administering to the subject an active agent for treating the inflammatory bowel disease that does not directly target TNF.
Dependencies are inferred from the claim text.